Publications by authors named "Marie Helene Schlageter"
Despite the advances in the understanding and treatment of myeloproliferative neoplasm (MPN), the disease remains incurable with the risk of evolution to acute myeloid leukemia or myelofibrosis (MF). Unfortunately, the evolution of the disease to MF remains poorly understood, impeding preventive and therapeutic options. Recent studies in solid tumor microenvironment and organ fibrosis have shed instrumental insights on their respective pathogenesis and drug resistance, yet such precise data are lacking in MPN.
View Article and Find Full Text PDFAcute graft-versus-host disease (GVHD) is still the major contributor to comorbidities and mortality after allogeneic hematopoietic stem cell transplantation. The use of plasmatic biomarkers to predict early outcomes has been advocated in the past decade. The purpose of this prospective noninterventional study was to test the ability of panels including 7 biomarkers (Elafin, HGF, IL2RA, IL8, REG3, ST2, and TNFRI), to predict day 28 (D28) complete response to steroid, D180 overall survival, and D180 nonrelapse mortality (NRM).
View Article and Find Full Text PDFRevisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement.
Br J Haematol
February 2022
Article Synopsis
- * They found that low erythropoietin levels (≤3.3 mUI/ml) and JAK2 mutations had similar positive predictive values for identifying true polycythemia, around 90% for both tests.
- * Notably, very low erythropoietin levels (≤1.99 mUI/ml) were 100% predictive for diagnosing polycythemia vera, suggesting a need to rethink how erythropoietin is used in diagnostic criteria for this disease.
Article Synopsis
- A phase 2 trial investigated the effectiveness of ruxolitinib in improving disease-free survival (DFS) in myelofibrosis patients prior to transplantation, involving 76 participants.
- Of the patients, 64 had donors, with significant transplantation success: 92% proceeded to transplant after ruxolitinib treatment, and 31% showed a partial response beforehand.
- After one year, overall survival was 68% and DFS was 55%, with better outcomes linked to HLA-matched sibling donors compared to unrelated donors.
Background: Thyroglobulin (Tg) assay in washout fluids of fine needles, after cervical lymph nodes aspiration, is used for detecting metastases from differentiated thyroid carcinomas. Assay methods are the same as for Tg in serum. However, with non-serum samples, methods require extensive validation to notably check for the absence of matrix effect.
View Article and Find Full Text PDFArticle Synopsis
- Researchers are studying how metabolic changes, particularly in amino acid pathways linked to the folate cycle, affect the effectiveness of cancer treatments in acute myeloid leukemia (AML).
- They found that lower levels of folate and a specific gene variant affecting the MTHFR enzyme can lead to resistance against certain cancer therapies targeting MYC in both lab models and patient samples.
- Supplementing with CH-THF, a product of the MTHFR enzyme, can potentially overcome this resistance, suggesting that assessing individual folate cycle status may help identify patients who could benefit most from MYC-targeting treatments.
Article Synopsis
- - The development of myeloproliferative neoplasms (MPNs) is linked to specific gene mutations in JAK2, MPL, or CALR, which are critical for diagnosis according to WHO standards.
- - In a study involving 1382 patients, rare and unexpected genetic profiles emerged, leading to challenges in accurately diagnosing MPNs due to mixed mutations and the need for additional genetic testing.
- - The findings highlight the importance of confirming mutations through direct Sanger sequencing and considering germline DNA alongside next-generation sequencing (NGS) for accurate interpretation and treatment decisions.
Almost one-half of patients developing graft-versus-host disease (GVHD) will not respond to standard first-line steroid treatment. Alpha-1 antitrypsin (AAT) is able to induce tolerance in preclinical models of GVHD. AAT alters the cytokine milieu, promotes a tolerogenic shift of dendritic cells, and skews effector T cells toward regulatory T cells.
View Article and Find Full Text PDFArticle Synopsis
- - Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) often lead to frequent relapses and poor survival rates with current treatments like chemotherapy and 5-azacitidine (AZA).
- - PRIMA-1 (APR-246) is a compound that restores the function of mutant p53 and can induce cell death (apoptosis) in tumor cells; it has shown effectiveness both alone and in combination with AZA in targeting MDS/AML cells with mutations.
- - The combination treatment of APR and AZA appears to work by downregulating the FLT3 pathway, allowing for more effective cell proliferation inhibition, suggesting that integrating APR-246 into standard treatments may improve
Article Synopsis
- The JAK2 mutation is crucial for diagnosing myeloproliferative neoplasms (MPN), and while qPCR is common, this study evaluates the effectiveness of next-generation sequencing (NGS) for detecting these mutations.
- Analysis of 427 patient DNA samples revealed strong agreement between qPCR and NGS when allelic burdens exceeded 2%, but NGS was less sensitive for lower burdens, missing some with qPCR values between 0.1 and 1%.
- The study identified various JAK2 variants through NGS, including a specific mutation that activates the JAK/STAT pathway, highlighting NGS as a reliable method to not only confirm mutations but also discover potentially significant new variants.
Objectives: Transaxillary robotic thyroidectomy surgery (TARS) has been reported to be a safe approach in patients with differentiated thyroid carcinoma, and oncological responses are promising.
Study Design: This study aimed to evaluate the oncological outcomes of TARS followed by radioiodine (RAI) therapy in patients with differentiated thyroid carcinoma. Between 2011 and 2016, patients treated for differentiated thyroid carcinoma by TARS in a single institution, followed by RAI, were retrospectively included.
Context: Prostate cancer stratification is based on tumour size, pretreatment PSA level, and Gleason score, but it remains imperfect. Current research focuses on the discovery and validation of novel prognostic biomarkers to improve the identification of patients at risk of aggressive cancer or of tumour relapse.
Objective: This systematic review by the Intergroupe Coopérateur Francophone de Recherche en Onco-urologie (ICFuro) analysed new evidence on the analytical validity and clinical validity and utility of six prognostic biomarkers (PHI, 4Kscore, MiPS, GPS, Prolaris, Decipher).
The aim of this study was to evaluate the pre-analytical factors contributing to uncertainty in thyroglobulin measurement in fluids from fine-needle aspiration (FNA) washout of cervical lymph nodes. We studied pre-analytical stability, in different conditions, of 41 samples prepared with concentrated solutions of thyroglobulin (FNA washout or certified standard) diluted in physiological saline solution or buffer containing 6% albumin. In this buffer, over time, no changes in thyroglobulin concentrations were observed in all storage conditions tested.
View Article and Find Full Text PDFGraft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission.
J Adolesc Young Adult Oncol
June 2017
Purpose: Adolescents and young adults (AYAs) with cancer are a unique group of patients in terms of disease incidence and biology, outcome, and psychosocial needs. This study aims to correlate the risk of graft-versus-host disease (GvHD) and age in a population of children and young adults with acute leukemia undergoing hematopoietic stem cell transplantation (HSCT) in first complete remission (CR).
Methods: We analyzed the outcome of 153 consecutive children (<15 years), AYAs (15-24 years), and adults (25-35 years) with lymphoblastic or myeloid acute leukemia in first CR who underwent HSCT with matched donors after myeloablative conditioning.
Metastatic melanoma is a rapidly spreading cancer whose prognosis remains poor although important therapy advances in recent years. Ipilimumab, an anti-CTLA-4 immunotherapy used in advanced melanoma, is an effective immunotherapy alone or combined with other agents but with few predictive biomarkers of response. Here, we sought to analyze the potential of S100B, MIA, soluble MICA, anti-MICA antibodies and LDH as serum biomarkers of response and survival in a cohort of 77 advanced melanoma patients subjected to ipilimumab.
View Article and Find Full Text PDFArticle Synopsis
- Myeloproliferative neoplasms are genetic disorders that lead to various blood-related issues, with limited treatment options available, one of which is interferon α (IFNα).
- In a study of 31 patients with essential thrombocythemia (ET) who have CALR mutations, all patients responded positively to IFNα, with significant reductions in their CALR mutant levels and some achieving complete molecular responses.
- Additional mutations in certain genes were found in some patients, which correlated with poorer responses to treatment, highlighting that these extra mutations can negatively influence the effectiveness of IFNα in CALR-mutated patients.
We have previously shown that a specific promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA) DNA vaccine combined with all-trans retinoic acid (ATRA) increases the number of long term survivors with enhanced immune responses in a mouse model of acute promyelocytic leukemia (APL). This study reports the efficacy of a non-specific DNA vaccine, pVAX14Flipper (pVAX14), in both APL and high risk myelodysplastic syndrome (HR-MDS) models. PVAX14 is comprised of novel immunogenic DNA sequences inserted into the pVAX1 therapeutic plasmid.
View Article and Find Full Text PDFArticle Synopsis
- Neutrophilic dermatoses are skin inflammatory disorders linked to conditions like autoimmune diseases and myeloproliferative disorders, with limited knowledge about their relationship with monoclonal immunoglobulin (MIg).
- The study analyzed 26 patients with neutrophilic dermatoses associated with MIg, examining clinical and biological factors, including cytokines and adhesion molecules.
- Findings indicate a significant link between IgA isotype MIg and neutrophilic dermatoses, revealing a unique inflammatory profile marked by elevated levels of specific molecules.
Anti-Müllerian hormone (AMH) levels fall during chemotherapy. Treatment-induced amenorrhoea is a reversible phenomenon, but few data are available on long-term AMH changes in breast cancer. The aim of the study was to describe serum AMH levels before, during and in the long term after chemotherapy, and to show a potential AMH recovery.
View Article and Find Full Text PDFObjectives: Chromogranin A (CgA) is the best-characterized biological marker common to neuroendocrine tumours and is therefore recommended for their diagnosis. The measurement of serum CgA is of great importance for reaching an early diagnosis and thus reducing the delay before treatment is instigated. The Kryptor CgA assay is the first fully automated assay available.
View Article and Find Full Text PDFPurpose: Our aims were to assess the feasibility of imaging hypoxia in cervical carcinoma with (18)F-fluoroerythronitroimidazole ((18)F-FETNIM) and to compare (18)F-FETNIM uptake with metabolic uptake of (18)F-FDG.
Patients And Methods: We included 16 patients with cervical carcinoma. After imaging with FDG, (18)F-FETNIM PET/CT was performed and tumor-to-muscle (T/M) ratio uptake was assessed.